A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered with an albumin-binding fatty acid side chain, heavily researched for glycemic control and weight management.
~165 hours (approx. 7 days)
GLP-1 Receptor
C187H291N45O59
Primarily administered via once-weekly subcutaneous injection; also available in an oral tablet formulated with the carrier sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC).
Multiple randomized controlled trials published in humans.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for Semaglutide: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C187H291N45O59
H-Aib-EGTFTSDVSSYLEGQAA-K(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-EFIAWLVRGRG-OH
Semaglutide is a modified analog of human GLP-1 (7-37) featuring two structural amino acid substitutions (alpha-aminoisobutyric acid at position 8 to resist DPP-4 degradation) and a spacer attached to a C18 diacid chain at lysine 26, affording extended non-covalent albumin binding and a 1-week biological half-life. It has been extensively investigated across massive multinational phase 3 trials (STEP and SUSTAIN series).
Selectively binds and activates the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric motility, and acting centrally in the hypothalamus to induce satiety.
Peer-reviewed publications, clinical trials, and preclinical research investigating Semaglutide.
The seminal STEP 1 clinical trial demonstrating average weight reductions of 14.9% in the semaglutide group versus 2.4% with placebo at 68 weeks.
The landmark SELECT trial establishing a statistically significant 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic patients treated with once-weekly semaglutide.
Head-to-head phase 3 trial demonstrating that the dual GIP/GLP-1 receptor co-agonist tirzepatide achieved superior glycemic control and weight reduction compared to semaglutide 1 mg.
Documented literature dosing intervals and published clinical trial protocols.
Frequency: Once weekly
“Initiated at 0.25 mg (250 mcg) weekly for 4 weeks, with 4-week step escalations to mitigate gastrointestinal side effects.”
Biological delivery routes and standardized laboratory reconstitution principles.
Primarily administered via once-weekly subcutaneous injection; also available in an oral tablet formulated with the carrier sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC).
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolNovel enteric carrier molecules and SNAC absorption enhancers demonstrate promising oral delivery parameters for therapeutic peptides.
Read ArticleMultinational clinical data confirms that once-weekly semaglutide reduces major adverse cardiovascular events by 20% in non-diabetic adults with obesity and cardiovascular disease.
Read ArticleMaster the underlying biology, pharmacokinetics, and reconstitution protocols relevant to Semaglutide.
How to differentiate preclinical rodent research from human double-blind randomized clinical trials. Understanding endpoints, p-values, and statistical power.
Why do some peptides degrade in minutes while others circulate for days? Exploring enzymatic cleavage, renal filtration, albumin binding, and chemical half-life engineering.
A deep biochemical comparison exploring how short amino acid chains differ from complex globular proteins in receptor docking, immunogenicity, and metabolic clearance.
Exploring why native peptides disappear within minutes: the omnipresence of circulating endopeptidases, aminopeptidases, and rapid renal filtration.
Compiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
